Genomic Classifier for Luminal Androgen Receptor Triple-Negative Breast Cancer

Jan 25, 2019
By Alice Goodman
TRIPLE-NEGATIVE breast cancer is a heterogeneous disease that comprises several subtypes, which may respond differently to therapy. Breast cancer researchers at the Mayo Clinic are developing a novel genomic signature that may improve the identification of the luminal androgen receptor vs basal (non–luminal androgen receptor) triple-negative breast cancer subtypes, which may better inform treatment selection. [...]

Novel data-driven approach for precision medicine

Nov 12, 2018
By Colette Gallagher @colettegallagher
Dr. Rani Kalari, a computational biologist, and lead author of a Mayo Clinic led study, published in JCO Clinical Cancer Informatics showed that combining multiple sources of data to predict the most effective drug choices for patients with cancer is feasible.[...]

Unlocking the power of genomics data: course offers new tools for discovery

Aug 6, 2018
By Sharon Rosen @sharonhrosen
Mayo Clinic researcher Krishna Rani Kalari, Ph.D., shared how she is applying novel computational approaches to analyze and visualize publically available large-scale cancer genomics data sets. She provided examples of how a researcher or a biologist with limited programming skills could mine multi-omics data with existing bioinformatics tools. She also presented novel omics-guided drug prioritization methods developed by her team. The goal of these algorithms is to identify mutations and dysregulated pathways that are associated with the tumor of an individual patient for personalized treatment.[...]